Verenium Appoints Holger Liepmann To Its Board Of Directors

         Verenium Appoints Holger Liepmann To Its Board Of Directors

-- Adds strong global commercial operations experience --

PR Newswire

SAN DIEGO, Feb. 26, 2013

SAN DIEGO, Feb. 26, 2013 /PRNewswire/ --Verenium Corporation (Nasdaq: VRNM),
a leading industrial biotechnology company focused on the development and
commercialization of high-performance enzymes, today announced that Michael
Zak will be leaving its Board of Directors effective March 31, 2013, and that
Holger Liepmann will be appointed to its Board of Directors, also effective
March 31, 2013.

(Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO)

"I am pleased to welcome Holger to Verenium's Board of Directors, as his
extensive global operations experience, which included very successful product
launches in the pharmaceutical, hospital and nutritional arena, will prove
especially important as we focus on growing our commercial business and
further diversifying our product portfolio," said Dr. James Cavanaugh,
Chairman of the Board of Verenium. "I'd also like to thank Michael Zak for
his many years of service to Verenium."

Mr. Liepmann retired two years ago from Abbott Laboratories, a leading global
health care company, where he spent 25 years in various positions gaining
progressively greater responsibilities in the company throughout his
career.Most recently, he served as Executive Vice President of Global
Nutrition where he was responsible for all facets of the company's second
largest business with sales exceeding $5.5 billion. In this role, Mr.
Liepmann helped the Global Nutrition group grow market share globally,
including becoming the market leader in the U.S. and significantly expanding
international sales. Prior to that, he served as Executive Vice President of
Abbott's Pharmaceutical Products Group, Senior Vice President of International
Operations of the company's ex-U.S. pharmaceutical and nutritional operations,
and several other positions with Abbott International, based in various parts
of the world.

Mr. Liepmann earned a bachelor's degree in Psychology from Dartmouth College
and a Masters in Business Administration from Stanford University.

About Verenium

Verenium, an industrial biotechnology company, is a global leader in
developing high-performance enzymes. Verenium's tailored enzymes are
environmentally friendly, making products and processes greener and more
cost-effective for industries, including the global food and fuel markets.
Read more at www.verenium.com.

Forward Looking Statements

Statements in this press release that are not strictly historical are
"forward-looking" and involve a high degree of risk and uncertainty. These
include, but are not limited to, statements related to Verenium's ability to
develop and/or commercialize its products, diversify its product portfolio,
enhance its manufacturing capabilities, capture near-term and longer-term
growth and prospects. Such statements are only predictions, and actual events
or results may differ materially from those projected in such forward-looking
statements. Factors that could cause or contribute to the differences
include, but are not limited to, risks associated with Verenium's strategic
focus, technologies, products and product candidates and product pipeline
(including Verenium's ability to identify, develop and commercialize new
products and product candidates, either independently or with collaborators or
partners, and market demand for those products and product candidates),
dependence on patents and proprietary rights, protection and enforcement of
its patents and proprietary rights, the commercial prospects of the industries
in which Verenium operates and sells products, Verenium's dependence on
manufacturing and/or license agreements, its ability to achieve milestones
under existing and future collaboration agreements, the ability of Verenium
and its partners to commercialize its technologies and products (including by
obtaining any required regulatory approvals) using Verenium's technologies,
the timing for launching any commercial products and projects, the ability of
Verenium and its collaborators to market and sell any products that it or they
commercialize, the development or availability of competitive products or
technologies, the future ability of Verenium to enter into and/or maintain
collaboration and joint venture or partnership agreements and licenses on a
timely basis or at all, and risks and other uncertainties more fully described
in Verenium's filings with the Securities and Exchange Commission, including,
but not limited to, Verenium's annual report on Form 10-K for the year ended
December 31, 2011 and any updates contained in its subsequently filed
quarterly reports on Form 10-Q . These forward-looking statements speak only
as of the date hereof, and Verenium expressly disclaims any intent or
obligation to update these forward-looking statements.

Contacts for Verenium:
Sarah Carmody
Sr. Corporate Communications Manager
858-431-8581
sarah.carmody@verenium.com

SOURCE Verenium Corporation

Website: http://www.verenium.com